Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: A gynecologic oncology group study
2011; Elsevier BV; Volume: 121; Issue: 2 Linguagem: Inglês
10.1016/j.ygyno.2010.11.023
ISSN1095-6859
AutoresJohn Farley, Leia M. Smith, Kathleen M. Darcy, Mark F. Brady, Jeffrey A. Bell, William P. McGuire, Michael J. Birrer,
Tópico(s)Sarcoma Diagnosis and Treatment
ResumoNuclear p27 expression was examined in non-invasive and invasive ovarian tumors from a cross-sectional study, and clinical relevance of p27 was evaluated in the primary tumors from women participating in two randomized phase III treatment trials.An immunohistochemistry assay was used to detect p27 in formalin-fixed paraffin-embedded ovarian tumors from 3 distinct sources.Among the initial 91 ovarian tumors tested, low p27 expression (<50% positive cells) was observed in 5.4% of non-invasive tumors versus 42.6% of invasive tumors (p 1.0 with an increased risk of death (hazard ratio=1.53; p=0.017).Low p27 expression could be associated with malignant transformation of the ovarian epithelium and FIGO stage. A cyclin E to p27 ratio >1.0 may be associated with shorter survival in these patients. Further study is required to confirm the trend for increased recurrences with low p27 expression in early stage disease.
Referência(s)